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ABSTRACT
Acute HIV infection is rarely recognized as the signs and symptoms are normally unspecifi c and 
can persist for days or weeks. The normal HIV course is characterized by a progressive loss of CD4+ 
cells, which normally leads to severe immunodefi ciency after a variable time interval. The mean 
time from initial infection to development of clinical AIDS is approximately 8-10 years, but it is 
variable among individuals and depends on a complex interaction between virus and host. Here we 
describe an extraordinary case of a man who developed Pneumocisits jiroveci pneumonia within one 
month after sexual exposure to HIV-1, and then presented with 3 consecutive CD4 counts bellow 
200 cells/mm3 within 3 months, with no other opportunistic disease. Although antiretroviral therapy 
(AZT+3TC+ATZ/r) was started, with full adherence of the patient, and genotyping indicating no 
primary antiretroviral resistance mutations, he required more than six months to have a CD4 resto-
ration to levels above 200 cells/mm3 and 10 months to HIV-RNA to become undetectable.
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INTRODUCTION
HIV infection is characterized by a progres-
sive loss of CD4+ cells, which normally leads to 
severe immunodefi ciency after a variable time 
interval. Following infection with HIV-1, the 
majority of individuals present with a clinical 
picture characterized by a mononucleosis-like 
syndrome, a transient drop in CD4+ cells, and 
a subsequent recovery of these initially reduced 
CD4+ T cell counts to near normal levels.1 The 
mean time from initial infection to develop-
ment of clinical AIDS is approximately 8-10 
years,2-5 but can vary among individuals and 
depends on the complex interaction between 
virus and host. The strongest predictor for the 
speed of HIV-1 disease progression is viral load 
set point, and infected subjects with high levels 
of viremia usually progress to AIDS faster than 
those with lower viral load.6,7 
Opportunistic infections that occur within 
the fi rst months after infection with HIV-1 are ex-
tremely rare, and are often misdiagnosed or missed. 
Patients and treating physicians can be misguided 
by a negative HIV-1 test within the preceding 
months. Here we describe a case of a homosexual 
man who developed Pneumocisits jiroveci  pneu-
monia within one month of infection by HIV-1. 
This case emphasizes that clinicians need to be 
aware of the possibility of opportunistic infections 
occurring during early HIV-1 infection.
CASE REPORT
A 28-year-old male patient presented on April 
4, 2005, with fever of 38o C, a rash on the upper 
limbs, which extended to the trunk and face af-
ter 2 days, night sweats, headache, myalgia and 
fatigue. After 7 days, the symptoms spontane-
ously disappeared. This episode was preceded by 
a single high-risk sexual exposure to a partner of 
unknown HIV serostatus, seven days before the 
onset of symptoms. Apart from this single risk 
exposure, the subject reported to be in a monoga-
mous relationship with his HIV-1-negative male 
partner that had no other risk factors for HIV in-
fection (tested HIV-1 negative in March 2005 and 
still negative at the latest measurement in Septem-
ber 2008). He was also tested negative for HIV-1 
on January 17, 2005 (antibody and p24 antigen 
negative), when an HIV-1 test was performed in 
a context of an acute episode of diarrhea. 
Two weeks after rash onset (on April 22, 
2005), the patient was seen at the emergency 
room of a private hospital complaining of cough 
and fever. A chest X-Ray showed interstitial 
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infi ltration and he was prescribed moxiﬂ oxacin (400 mg/d, 
PO). There was no improvement, and after 48 hours he re-
turned to the hospital with persistent symptoms, malaise and 
shortness of breath. A chest computerized tomography scan 
revealed an interstitial infi ltrate suggestive of P. jiroveci pneu-
monia. His arterial oxygen pressure was 70 mmHg, with an 
O
2
 saturation index of 96%. He was hospitalized, and received 
prednisone 1mg/kg, and sulphametoxazole plus thrimetho-
prim (800/160 mg, qid, 21d). Acid fast baciloscopy (AFB) and 
blood pyogenic cultures were negative. Fever disappeared af-
ter 48 hours, and clinical symptoms resolved. A new HIV-1 
serological test (EIA) performed on April 24, 2005, was posi-
tive for HIV (p24 Gag; p 41 Env) antibodies, which was con-
fi rmed by Western Blot (p17, p31, p51, p55, p66 = negative, 
p24 weakly positive, Gp41, Gp120, Gp160 positive). 
A CD4+ T cell count performed on May 24, 2005, was 24 
cells/ mm3, while the CD8+ T cell count was 251 cells/ mm3. 
HIV-1 viral load was quantifi ed using NASBA (NucliSENS, 
BioMerieux) and was over 7,000,000 copies HIV-1 RNA 
per mL plasma. At a follow-up visit on June 08, 2007, the 
HIV-1 viral load had decreased to 3,200,000 copies/mL 
and CD4+ and CD8+ T cell counts had increased to 61 
and 799 cells/mm3, respectively, without the initiation of 
any antiretroviral therapy. A genotyping test for potential 
antiretroviral drug resistance mutations performed on May 
24, 2005, using the Trugene HIV-1 assay showed no evi-
dence of drug-resistance mutations, mRNA ﬂ ow cytometric 
analysis using ViroTect, Invirion Diagnostics Inc.8 revealed a 
dual-tropic virus infection. He was discharged from hospital 
on May 11, 2005, without any symptoms.
He returned to hospital on June 11, 2005, with a clinical 
picture suggestive of upper respiratory tract infection (fever, 
headache, nasal congestion). An X-Ray of his face showed 
sinusitis, which was successfully treated with amoxacillin-
clavulanate (500/125 mg, tid, 14d). His plasma viral load 
was 2,900,000 copies/mL; CD4+ cells count had increased 
to 136 cells/mm3 (June 14, 2005). The patient was started 
on antiretroviral (ARV) therapy using AZT + 3TC + ATV/r 
on June 14, 2005, and then discharged. After 2 weeks of 
therapy (June 28, 2005), his viral load decreased to 11,000 
copies/mL and CD4 count was 62 cells/mm3. Four weeks 
after (July 12, 2005), his plasma viral load was 320 cop-
ies/mL, while his CD4+ cells count has increased to 196 
cells/mm3. Besides report of full adherence to ARV therapy, 
measures 3 and 5 months after initiation of viral load were 
210 and 1400 copies/mL, respectively; he only became un-
detectable 9 months after and remained as such since then 
(36 months) (Figure 1). The patient’s HLA type was Locus 
A*23, 24 B*1503, 35 Cw*02, 04. 
DISCUSSION
The natural history of HIV infection is highly variable.2,9 
However, most infected individuals remain free of symptoms 
for 6-10 years after initial infection, and a subset of infected 
individuals do not progress to AIDS after being infected for 
more than 25 years (so called “long-term non-progressors”). 
Differences in the speed of HIV-1 disease progression have 
been linked to several factors; most consistently to genetic 
factors, including chemokine polymorphisms and the ex-
pression of specifi c HLA class I or KIR alleles.10,11 On the 
other hand, there are rare individuals who progress to AIDS 
in a very short time after initial exposure to HIV. In MACS 
cohort a rate < 1% of rapid progression to AIDS within 12 
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months of infection was reported with 0.007% of individuals 
reaching a CD4+ cell count less than 200 cells/ mm3 within 
6 months of infection, and 0.045% within one year.12,13 The 
factors that are responsible for the rapid progression of dis-
ease in these individuals are not known. 
Recently, a case of a man who developed AIDS, including 
the need for ARV therapy within 4-5 months after acute infec-
tion, was reported, and potential co-factors, such as life-style, 
use of drugs, or even an exceptionally virulent resistant strain 
of HIV have been discussed in this context.14 There are some 
cases of P. jiroveci in literature, but all recovered CD4 levels 
without ARV therapy within four months after symptoms.15 
In the present case, the study subject did not report any drug 
use and he had stable HIV negative sex-partner. It was previ-
ously reported that HLA-B*35, Cw*04 and A*68 were asso-
ciated with increased risk of fast progression to AIDS;16-19 of 
these, our patient has the fi rst two antigens. In addition, the 
HIV-1 strain isolated was sensitive to all current antiretrovi-
ral drugs, and belonged to subtype B, the most frequent viral 
subtype circulating in Bahia and associated with non-aggres-
sive progression,20 however, the dual tropic viral profi le was 
related to a increased risk of fast progression.14 Most impor-
tantly, this case emphasizes that physicians must be aware that 
life threatening opportunistic infections can occur during this 
early phase of infection. Acute HIV-1 infection can occasion-
ally result in a rapid and dramatic loss of CD4+ T cells. 
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